Australia’s Telix Pharmaceuticals, which makes a diagnostic drug used alongside Novartis’ treatment for prostate cancer, is also on the warpath about copycats being made in local laboratories ...

And as you're about to notice, not only were the pharmaceutical products they ... 125,000 people worked for Novartis – 47% in Europe, 24% in Africa, Asia and Australia, 21% in the USA and ...

Lead study author Timothy Hughes, of the South Australian Health and Medical ... was considered at the time to be one of Novartis’ ‘wild card’ products, a group that the company felt was ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

MELBOURNE, Australia and OXFORD, United Kingdom, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing ...

Novartis is another leading drugmaker with an extensive lineup of approved products. Several of the company's medicines are doing much of the heavy lifting in driving its top line in the right ...

As a host of generics circle the gates, Novartis has lost another bid to ... though none of the copycat products have launched. Aside from looming exclusivity challenges, Entresto is one of ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...

Novartis has decided to focus on other growth ... Even if they might not have approved GLP-1 products, simply reporting encouraging results in clinical trials has often been enough to ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...

Despite diagnostic and therapeutic advances, mortality and the multi-systemic health impact of SMA continue to be experienced ...